Based on this as well as on multiple evidence indicating that CTSD and LOXL2 have pro-proliferative functions, inhibition of CTSD and LOXL2 have been suggested as a therapeutic approach for various cancers [55–60]. The gene discussed is LOXL2; the disease is cancer.